DOCSLIB.ORG

Hypertrophic Cardiomyopathy 2011 Pocket Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hypertrophic Cardiomyopathy 2011 Pocket Guide ACCF/AHA Pocket Guideline Adapted from the 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy November 2011 Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons © 2011 by the American College of Cardiology Foundation and the American Heart Association, Inc. The following material was adapted from the 2011 ACCF/AHA Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy (J Am Coll Cardiol 2011;XX:XX–XX). This pocket guideline is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource. org) and the American Heart Association (my.americanheart.org). For copies of this document, please contact Elsevier Inc. Reprint Department, e-mail: [email protected]; phone: 212-633-3813; fax: 212-633-3820. Permissions: Multiple copies, modification, alteration, enhancement, and/ ordistribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier’s permission department at [email protected]. Contents 1. Introduction .........................................................................................3 2. Clinical Definition ................................................................................6 3. Genetic Testing Strategies/Family Screening .....................................7 4. Genotype-Positive/Phenotype-Negative Patients .............................9 5. Echocardiography .............................................................................. 10 6. Stress Testing ..................................................................................... 14 7. Cardiac Magnetic Resonance ............................................................ 15 8. Detection of Concomitant Coronary Disease ................................... 17 9. Asymptomatic Patients ..................................................................... 19 10. Pharmacologic Management ........................................................... 21 11. Invasive Therapies ........................................................................... 26 12. Pacing .............................................................................................. 29 13. Sudden Cardiac Death Risk Stratification ..................................... 30 14. Selection of Patients for Implantable Cardioverter-Defibrillators ...32 15. Participation in Competitive or Recreational Sports and Physical Activity ...................................................................... 36 16. Management of Atrial Fibrillation ................................................. 38 17. Pregnancy/Delivery ........................................................................ 41 2 1. Introduction The impetus for the guidelines is based on an appreciation of the frequency of this clinical entity and a realization that many aspects of clinical management, including the use of diagnostic modalities, genetic testing, utilization of implantable cardioverter-defibrillators (ICDs), and therapies for refractory symptoms lack consensus. The discussion and recommendations about the various diagnostic modalities apply to patients with established HCM and to a variable extent to patients with a high index of suspicion of the disease. Classification of Recommendations The ACCF/AHA classifications of recommendations and levels of evidence are utilized, and described in more detail in Table 1. 3 Table 1. Applying ClassificationTableTable 1. of Applying1. Recommendations Applying Classification Classification and Level of ofRecommendations of Evidence and Level of Evidence Recommendations and Level of Evidence SIZE OF TREAT MENSIZET E FFECOF TREAT T MENT E FFECT CLASS I CLASSCLASS IIa I CLASSCLASS IIb IIa CLASSCLASS III IIb No Benefit CLASS III No Benefit Benefit >>> Risk BenefitBenefit >> >>> Risk Risk BenefitBenefit > >> Risk Risk orBenefit CLASS > III Risk Harm or CLASS III Harm Additional studies with AdditionalAdditional studies studies with with broad AdditionalProcedure/ studies with broad Procedure/ Procedure/Treatment Procedure/Treatment Test Treatment Test Treatment focused objectives needed objectivesfocused objectivesneeded; additional needed objectives needed; additional SHOULD be performed/ SHOULD be performed/ COR III: Not No Proven COR III: Not No Proven administered IT administeredIS REASONABLE to per- registryIT IS REASONABLE data would be to helpful per- Noregistry benefit dataHelpful would Benefitbe helpful No benefit Helpful Benefit form procedure/administer Procedure/Treatmentform procedure/administer CORProcedure/Treatment III: Excess Cost Harmful COR III: Excess Cost Harmful treatment MAYtreatment BE CONSIDERED HarmMAY BE w/oCONS BenefitIDERED to Patients Harm w/o Benefit to Patients or Harmful or Harmful T T LEVEL A n RecommendationLEVEL A that n Recommendationn Recommendation in thatfavor n nRecommendation’s Recommendation in favor n nRecommendation Recommendation’s that n Recommendation that FFEC FFEC procedure or treatment of proceduretreatment or proceduretreatment usefulness/efficacyof treatment or procedure less procedureusefulness/efficacy or treatment less is procedure or treatment is E Multiple populations E Multiple populations is useful/effective beingis useful/effective useful/effective wellbeing established useful/effective notwell useful/effective established and may T not useful/effective and may evaluated* T evaluated* n Sufficient evidence from n Somen Sufficient conflicting evidence evidence from n nGreater Some conflicting evidence ben harmful Greater conflicting be harmful MEN Data derived from multiple MEN Data derived from multiple multiple randomized trials frommultiple multiple randomized randomized trials n n T evidencefrom multiple from multiple randomized T evidenceSufficient from evidence multiple from Sufficient evidence from randomized clinical trials or meta-analysesrandomized clinical trials trialsor meta-analyses or meta-analyses randomizedtrials or meta-analyses trials or multiplerandomized randomized trials or trials or multiple randomized trials or or meta-analyses or meta-analyses meta-analyses meta-analysesmeta-analyses meta-analyses LEVEL B n RecommendationLEVEL B that n Recommendationn Recommendation in thatfavor n nRecommendation’s Recommendation in favor n nRecommendation Recommendation’s that n Recommendation that procedure or treatment of proceduretreatment or proceduretreatment usefulness/efficacyof treatment or procedure less procedureusefulness/efficacy or treatment less is procedure or treatment is ION) OF TREA Limited populations ION) OF TREA Limited populations S S is useful/effective beingis useful/effective useful/effective wellbeing established useful/effective notwell useful/effective established and may not useful/effective and may evaluated* evaluated* n Evidence from single n Somen Evidence conflicting from single n nGreater Some conflicting ben harmful Greater conflicting be harmful Data derived from a Data derived from a randomized trial or evidencerandomized from trialsingle or evidenceevidence from from single single n evidenceEvidence fromfrom singlesingle n Evidence from single single randomized trial single randomized trial Y (PRECI randomized trial or Y (PRECI nonrandomized studies nonrandomized studies randomizedrandomized trial trial or or randomizedrandomized trial trial or or randomized trial or T or nonrandomized studies T or nonrandomized studies nonrandomized studies nonrandomizednonrandomized studies studies nonrandomizednonrandomized studies studies nonrandomized studies AIN AIN T T LEVEL C n RecommendationLEVEL C that n Recommendationn Recommendation in thatfavor n nRecommendation’s Recommendation in favor n Recommendation’s ER ER n Recommendation that n Recommendation that C C procedure or treatment is of proceduretreatment or proceduretreatment is usefulness/efficacyof treatment or procedure less usefulness/efficacy less Very limited populations Very limited populations procedure or treatment is procedure or treatment is useful/effective beinguseful/effective useful/effective wellbeing established useful/effective well established evaluated* evaluated* not useful/effective and may not useful/effective and may E OF E OF n Only expert opinion, case n Onlyn Only diverging expert opinion, expert case n nOnly Only diverging diverging expert expert n Only diverging expert T Only consensus opinion T Only consensus opinion be harmful be harmful studies, or standard of care opinion,studies, case or standard studies, of care opinion,opinion, case case studies, studies, or opinion, case studies, or of experts, case studies, of experts, case studies, n Only expert opinion, case n Only expert opinion, case IMA IMA or standard of care standardor standard of care of care standard of care or standard of care or standard of care studies, or standard of care studies, or standard of care EST EST Suggested phrases for shouldSuggested phrases for is reasonableshould may/mightis reasonable be considered CORmay/might III: be consideredCOR III: COR III: COR III: writing recommendations is recommendedwriting recommendations canis be recommended useful/effective/beneficial may/mightcan be useful/effective/beneficial be reasonable Nomay/might Benefit be reasonableHarm No Benefit Harm
Load more

Recommended publications
  • And Its Obstructive Form, Idiopathic Hypertrophic Subaortic Stenosis (IHSS), in Pediatrics
    Asymmetric septal hypertrophy (ASH) and its obstructive form, idiopathic hypertrophic subaortic stenosis (IHSS), in pediatrics ALBERT K. HARVEY, DD. Oklahoma City, Oklahoma IHSS. The father had no siblings, but two uncles had Although idiopathic hypertrophic died suddenly of heart disease at early ages. subaortic stenosis usually occurs in Case 1 adults, the possibility of its presence in children must not be overlooked. It An 18-year-old white girl said she had not experienced dyspnea, exercise intolerance, syncope, or chest pain. She has been reported even as early as was a senior in high school and had participated in dra- infancy and in stillborn fetuses. The matic and athletic activities. Physical examination condition appears to be genetically showed the pulse rate to be 74 and the blood pressure transmitted, with the natural history 110/64 mm. Hg. Pulses on the upper and lower ex- one of progressive disease. The tremities were strong and symmetric. The point of atypical location of an aortic stenosis maximum intensity (PMI) was not enlarged, and no type murmur is a clue to early thrill or precordial heave was perceptible. There was a diagnosis. Echocardiography is Grade 2/6 harsh systolic ejection murmur along the lower confirmative of a diagnosis. Four case left sternal border, which was transmitted well to the reports are presented. apex. No diastolic component was present. The phono- cardiogram showed an intermittent fourth heart sound. An x-ray film of the chest showed the heart size and vascularity of the lung field to be normal. An elec- trocardiogram (EKG) revealed left ventricular hyper- trophy with marked ST and T wave changes in the left precordial leads.
    [Show full text]
  • Understanding Cardiomyopathy: Practical Guidelines
    Chapter 30 Understanding Cardiomyopathy: Practical Guidelines Asha Moorthy, Jain T Kallarakkal HYPERTROPHIC CARDIOMYOPATHY genes predominate in frequency. Beta-myosin heavy chain (the first identified), myosin-binding protein C and cardiac troponin T Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder probably comprise more than one half of the genotyped patients to caused by mutations in 1 of the 12 sarcomeric or nonsarcomeric date. Seven other genes each account for fewer cases: regulatory and genes and is recognized as the most common cause of sudden cardiac essential myosin light chains, titin, alpha-tropomyosin, alpha-actin, death (SCD) in the young and an important substrate for disability cardiac troponin I and alpha-myosin heavy chain. at any age. It affects men and women equally and occurs in many races and countries. The clinical diagnosis of HCM is established most easily and reliably with two-dimensional echocardiography by Clinical Course demonstrating left ventricular hypertrophy (LVH) which is typically asymmetric in distribution, and showing virtually any diffuse or Adverse clinical course proceeds along one or more of the following segmental pattern of left ventricular (LV) wall thickening. LV wall pathways, which ultimately dictate treatment strategies: (1) high thickening is associated with a nondilated and hyperdynamic risk for premature, sudden and unexpected death; (2) progressive chamber, in the absence of any other cardiac or systemic disease symptoms like exertional dyspnea, chest pain and impaired
    [Show full text]
  • Cardiac Surgery
    NON-PROFIT ORG. U.S. POSTAGE UAB Insight on Heart and Vascular Disease PAID PERMIT NO. 1256 410 • 500 22nd Street South BIRMINGHAM, AL Insight 1530 3rd ave S ON HEART AND VASCULAR DISEASE birmingham al 35294-0104 UAB Division of Cardiovascular Disease medicine.uab.edu/cardiovasculardisease UAB Division of Cardiothoracic Surgery medicine.uab.edu/cardiothoracicsurgery UAB Section of Vascular Surgery and Endovascular Therapy medicine.uab.edu/vascularsurgery Combined Therapy UAB Ambassador Program for Peripheral Vascular Disease The Ambassador Program gives referring physicians complete access to patient notes, letters, reports, and other data through a Catheter Ablation of secure Web portal. To join this program, please contact Physician Tachycardia Services at 1.800.822.6478. Minimally Invasive Pulmonary Thromboendarterectomy Clinic Cardiac Surgery welcOme 3 cOnTents Uab inSighT Welcome to the first issue of UAB Insight on Heart and Vascular On hearT and Disease, designed to keep you informed about UAB’s leading role in Cardiothoracic Surgery VaScUlar diSeaSe evaluation and treatment of cardiac and vascular diseases. UAB con- FALL 2009 sistently ranks among the top 30 cardiac programs rated in U.S. News Minimally Invasive Cardiac Surgery ... 2 & World Reports, and is a regional, national, and international referral VOlUme 1, nUmber 1 center for cardiac and vascular disease diagnosis and treatment. Adult Congenital Heart Disease ........ 3 With expertise in every major area of heart and vascular diseases, and James Kirklin, MD E D I T O R I N C H I E F as home to the Southeast’s largest and most technologically advanced Pulmonary Thromboendarterectomy Julius Linn, MD Heart and Vascular Center, we offer innovative, scientifically based Clinic .................................................
    [Show full text]
  • Heart & Vascular Institute
    Sydell and Arnold Miller Family Heart & Vascular Institute 9500 Euclid Avenue, Cleveland, OH 44195 ClevelandClinic.org 2016 Outcomes 17-OUT-413 108369_CCFBCH_Cov_acg.indd 1 8/31/17 12:22 PM Measuring Outcomes Promotes Quality Improvement This project would not have been possible without the commitment and expertise of a team led by Umesh Khot, MD; Mouin Abdallah, MD; Sandra Hays; and Jagina McIntyre. Graphic design and photography were provided by Brian Kohlbacher and Cleveland Clinic’s Center for Medical Art and Photography. © The Cleveland Clinic Foundation 2017 108369_CCFBCH_Cov_acg.indd 2 9/19/17 10:57 AM Measuring and understanding outcomes of medical treatments promotes quality improvement. Cleveland Clinic has created a series of Outcomes books similar to this one for its clinical institutes. Designed for a physician audience, the Outcomes books contain a summary of many of our surgical and medical treatments, with a focus on outcomes data and a review of new technologies and innovations. The Outcomes books are not a comprehensive analysis of all treatments provided at Cleveland Clinic, and omission of a particular treatment does not necessarily mean we do not offer that treatment. When there are no recognized clinical outcome measures for a specific treatment, we may report process measures associated with improved outcomes. When process measures are unavailable, we may report volume measures; a relationship has been demonstrated between volume and improved outcomes for many treatments, particularly those involving surgical and
    [Show full text]
  • Surgical Septal Myectomy Outcome for Obstructive Hypertrophic Cardiomyopathy After Alcohol Septal Ablation
    1065 Original Article Surgical septal myectomy outcome for obstructive hypertrophic cardiomyopathy after alcohol septal ablation Qiulan Yang1^, Changsheng Zhu1, Hao Cui2, Bing Tang3, Shengwei Wang3, Qinjun Yu4, Shihua Zhao5, Yunhu Song1, Shuiyun Wang1 1Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MI, USA; 3Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University & Beijing Institute of Heart, Beijing, China; 4Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 5Department of Magnetic Resonance Imaging, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Contributions: (I) Conception and design: S Wang; (II) Administrative support: C Zhu, H Cui, B Tang, S Wang, S Zhao; (III) Provision of study materials or patients: C Zhu; (IV) Collection and assembly of data: Q Yang; (V) Data analysis and interpretation: C Zhu, H Cui, B Tang, S Wang, S Zhao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Shuiyun Wang. Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beilishi Road 167, Xicheng District, Beijing 100037, China. Email: [email protected]. Background: Although surgical treatment of residual obstruction after alcohol septal ablation (ASA) is often challenging in patients with obstructive hypertrophic cardiomyopathy (OHCM) there are very few relevant clinical reports. Thus, outcomes of surgical septal myectomy (SSM) in this subgroup of patients remain to be determined.
    [Show full text]
  • Asymmetric Septal Hypertrophy in Patients with Aortic Stenosis: an Adaptive Mechanism Or a Coexistence of Hypertrophic Cardiomyopathy?
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE J AM cou,providedCARDIOl by Elsevier - Publisher783 Connector 1983.1(3)783-9 Asymmetric Septal Hypertrophy in Patients With Aortic Stenosis: An Adaptive Mechanism or a Coexistence of Hypertrophic Cardiomyopathy? OTTO M. HESS, MD, JAKOB SCHNEIDER, MD, MARCO TURINA, MD, JOHN D. CARROLL, MD, FACC, MARTIN ROTHLIN, MD, HANS P. KRAYENBUEHL, MD Zurich, Switzerland Myocardial histologic features andventricular left dy• 1 and 2 (26.5 versus 29.1IJ.; NS), but muscle fiber di• namics were assessed in 24 patients with severe aorticameter of the septum in group 1 was significantlysmaller stenosis, 12 with (group 1) and 12 without (group(24.4 2) IJ.; P < 0.01) than that ofanterolateral the wall in associated asymmetric septalhypertrophy.In 10patients group 2. No morphologic abnormalities typical for hy• from group 1,echocardiographyshowed a septal/pos• pertrophic cardiomyopathy (fiberdisarray)were seen in teriorwall ratio of 1.5; in the other 2, asymmetric septalsamples from the patients in either group. By 18 months hypertrophywas diagnosed by direct inspection at thepostoperatively, septal wall thickness had decreased sig• time of surgery. Septal myectomy in all 12 patientsnificantly in from 2.0 to 1.5 em< (p0.01) and posterior group 1 was completed at the time of aortic valvewall re• thickness from 1.4 to 1.2 cm< (p0.05) in group 1. In group 2, septal wall thickness decreased from 1.5 placement. Septal histologicfeatures were assessedfrom to 1.3 em (NS) and posterior wall thickness from 1.4 to surgical specimens in 10 patients in groupTransseptal 1.
    [Show full text]
  • Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy Joseph A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy Joseph A. Dearani, MD, and Gordon K. Danielson, MD ransaortic septal myectomy is currently considered to tion of the LVOT gradient is important so that a compar- Tbe the most appropriate surgical treatment for pa- ison can be made with postmyectomy measurements. tients with obstructive hypertrophic cardiomyopathy Standard cardiopulmonary bypass with mild to moderate (HCM) and severe symptoms unresponsive to medical hypothermia (30-34°C) is used and the left heart is vented therapy.1-18 However, there is a significant learning curve with a catheter inserted through the right superior pulmo- for this procedure, and early surgical experience was as- nary vein. Myocardial protection, especially important be- sociated with complications of complete heart block, ven- cause of the severe ventricular hypertrophy, is begun with tricular septal defect, injury to the aortic or mitral valves, a generous infusion of cold blood cardioplegia (800-1000 and incomplete relief of obstruction. Current surgical re- mL) into the aortic root followed by additional doses given sults are vastly improved, although the reported experi- selectively into the left and right coronary ostia every 20 ence in North America is limited to a few centers. minutes. For more complex and lengthy procedures, top- ical cooling with ice-cold saline is applied, and an insulat- Surgical Technique ing pad is placed behind the left ventricle. After the extended left ventricular septal myectomy is Over the last three decades, our technique of septal myec- performed, the resected area can be deepened with a ron- tomy has evolved from the classic Morrow myectomy (Fig geur.
    [Show full text]
  • Data Element Specifications
    California CABG Outcomes Reporting Program (CCORP) Data Element Specifications Version 7.1 May 5, 2019 California CABG Outcomes Reporting Program Data Element Specifications Version 7.1, dated May 5, 2019 (1) Medical Record Number: (A) Format: Alphanumeric, length 12 (B) Valid Values: Free text (C) Category: Demographics (D) Definition/Description: Indicate the patient's medical record number at the hospital where surgery occurred. (2) Type of Coronary Artery Bypass Graft (CABG): (A) Format: Numeric, length 1 (B) Valid Values: 1 = Isolated CABG; 3 = CABG + Valve; 4= Other non-isolated CABG (C) Category: Operative (D) Definition/Description: Indicate the type of CABG. (i) Type of CABG should be coded Isolated CABG if none of the procedures listed in this subsection was performed concurrently with the coronary artery bypass surgery. (a) Valve repairs or replacements (b) Operations on structures adjacent to heart valves (papillary muscle, chordae tendineae, traebeculae carneae cordis, annuloplasty, infundibulectomy) (c) Ventriculectomy when diagnosed preoperatively as a rupture, aneurysm or remodeling procedure. Excludes 1) sites intra-operatively diagnosed, 2) patch applications for site oozing discovered during surgery and 3) prophylactic patch applications to reduce chances of future rupture (d) Repair of atrial and ventricular septa, excluding closure of patent foramen ovale (e) Excision of aneurysm of heart (f) Head and neck, intracranial endarterectomy (g) Other open heart surgeries, such as aortic arch repair, pulmonary endarterectomy
    [Show full text]
  • Severe Mitral Annular Calcification
    JACC: CARDIOVASCULAR IMAGING VOL. 9, NO. 11, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jcmg.2016.09.001 STATE-OF-THE-ART PAPERS Severe Mitral Annular Calcification Multimodality Imaging for Therapeutic Strategies and Interventions Mackram F. Eleid, MD, Thomas A. Foley, MD, Sameh M. Said, MD, Sorin V. Pislaru, MD, PHD, Charanjit S. Rihal, MD, MBA ABSTRACT Mitral annular calcification (MAC) is a chronic degenerative process associated with advanced age and conditions predisposing to left ventricular hypertrophy. Assessment of mitral valve disease in patients with severe MAC can be a challenge. When severe MAC results in mitral stenosis or regurgitation, multimodality imaging with 2-dimensional, 3-dimensional, and Doppler echocardiography and cardiac computed tomography angiography can delineate the severity and pathoanatomic features to help guide therapeutic strategies. New approaches using computer-assisted simulation of transcatheter valves and novel percutaneous and surgical techniques are being used to devise effective alternative strategies to conventional mitral valve replacement in this high-risk group of patients. (J Am Coll Cardiol Img 2016;9:1318–37) © 2016 by the American College of Cardiology Foundation. itral annular calcification (MAC) is a being investigated, offering hope for this challenging M chronic degenerative process that, when group of patients. severe, can result in mitral stenosis (MS) and/or mitral regurgitation (MR). The prevalence of PATHOPHYSIOLOGY OF MAC significant MS due to severe MAC is increasing in the developed world due to the growing population MAC is a result of slowly progressive calcification of ofelderlypatientsandriskfactorssuchashyperten- the fibrous mitral annulus (Figure 1) (1).
    [Show full text]
  • Magnetic Resonance Imaging of Non‑Ischemic Cardiomyopathies: a Pictorial Essay
    Editor-in-Chief: Vikram S. Dogra, MD OPEN ACCESS Department of Imaging Sciences, University of Rochester Medical Center, Rochester, USA HTML format Journal of Clinical Imaging Science For entire Editorial Board visit : www.clinicalimagingscience.org/editorialboard.asp www.clinicalimagingscience.org PICTORIAL ESSAY Magnetic Resonance Imaging of Non‑ischemic Cardiomyopathies: A Pictorial Essay Cristina I Olivas‑Chacon, Carola Mullins, Kevan Stewart, Nassim Akle, Jesus E Calleros, Luis R Ramos‑Duran Department of Radiology, Texas Tech University Health Science Center El Paso, El Paso, Texas, USA Address for correspondence: Dr. Cristina Ivette Olivas Chacon, ABSTRACT Department of Radiology, 4800 Alberta Avenue, El Paso, Non-ischemic cardiomyopathies are defined as either primary or secondary diseases of Texas ‑ 79905, USA. the myocardium resulting in cardiac dysfunction. While primary cardiomyopathies are E‑mail: [email protected] confined to the heart and can be genetic or acquired, secondary cardiomyopathies show involvement of the heart as a manifestation of an underlying systemic disease including metabolic, inflammatory, granulomatous, infectious, or autoimmune entities. Non-ischemic cardiomyopathies are currently classified as hypertrophic, dilated, restrictive, or unclassifiable, including left ventricular non-compaction. Cardiovascular Magnetic Resonance Imaging (CMRI) not only has the capability to assess cardiac morphology and function, but also the ability to detect edema, hemorrhage, fibrosis, and intramyocardial deposits,
    [Show full text]
  • Targeting Alcohol Septal Ablation in Patients with Obstructive
    Journal of Clinical Medicine Article Targeting Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy Candidates for Surgical Myectomy: Added Value of Three-Dimensional Intracoronary Myocardial Contrast Echocardiography Giovanni La Canna 1,*, Iside Scarfò 1, Irina Arendar 1, Antonio Colombo 2, Lucia Torracca 3, Davide Margonato 4, Matteo Montorfano 4 and Ottavio Alfieri 5 1 Applied Diagnostic Echocardiography Unit, IRCCS Humanitas Clinical and Research Center, 20089 Rozzano, Italy; [email protected] (I.S.); [email protected] (I.A.) 2 Interventional Cardiology Unit, IRCCS Humanitas Clinical and Research Center, 20089 Rozzano, Italy; [email protected] 3 Cardiac Surgery, IRCCS Humanitas Clinical and Research Center, 20089 Rozzano, Italy; [email protected] 4 Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] (D.M.); [email protected] (M.M.) 5 Cardiac Surgery Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; ottavio.alfi[email protected] * Correspondence: [email protected]; Tel.: +39-33-5674-4319 Citation: La Canna, G.; Scarfò, I.; Abstract: Background: Myocardial contrast two-dimensional echocardiography (MC-2DE) is widely Arendar, I.; Colombo, A.; Torracca, L.; Margonato, D.; Montorfano, M.; used to address alcohol septal ablation (ASA) in obstructive hypertrophic cardiomyopathy (HCM). Alfieri, O. Targeting Alcohol Septal Owing to its limited cut-planes, MC-2DE may inaccurately identify the contrast misplacement Ablation in Patients with Obstructive associated with an unsuccessful or complicated ASA outcome. Objective: The aim of this study Hypertrophic Cardiomyopathy was to assess the added value of myocardial contrast three-dimensional echocardiography (MC- Candidates for Surgical Myectomy: 3DE) compared with MC-2DE to identify the appropriate matching between the target septal zone Added Value of Three-Dimensional (TSZ) and coronary artery branch for safe and long-term effective ASA in HCM patients.
    [Show full text]
  • Newyork-Presbyterian 2017 Outcomes and Quality Report in Cardiovascular Services
    NewYork-Presbyterian Cardiovascular Services 2017 Outcomes and Quality Report NewYork-Presbyterian Cardiology and Heart Surgery ranks #3 in the nation. NewYork-Presbyterian Cardiovascular Services 2017 Outcomes and Quality Report Welcome 1 Measures of Distinction 2 Innovations at a Glance 3 Complex Cardiac Care Adult Congenital Heart Disease 4 Advanced Heart Failure 6 Arrhythmias 10 Coronary Artery Disease 12 Hypertrophic Cardiomyopathy 15 Pulmonary Hypertension 16 Valve Disease 18 Aortic Disease 23 NewYork-Presbyterian Today 26 3D fl uorescence deconvolution micrograph of stacked images showing adrenergic receptors (red) clustered around the nucleus of a myofi bril in the heart tissue of a heart failure patient For More Information nyp.org/amazingadvances Welcome Dear Colleague: We are pleased to bring you our 2017 Outcomes and Quality Report in Cardiovascular Services. The strength of our cardiology, interventional cardiology, and cardiac surgery programs is derived from the exceptional clinical, scientic, and educational resources made possible by the partnership of NewYork-Presbyterian, Columbia University Medical Center, and Weill Cornell Medicine. These programs are among the largest and most comprehensive in the nation, bringing together faculty that have made transformative contributions to their specialties – from adult congenital heart disease to advanced heart failure and complex valve disease. Our patients benet from exceptional heart teams, whose multispecialty members provide Dr. Steven J. Corwin collaborative and integrated care that optimizes their outcomes. Our physicians treat the most challenging cases, applying expertise that crosses and often combines the skills of cardiologists, interventionalists, and surgeons to meet the unique needs of each patient. This collegiality is a hallmark of our cardiology and heart surgery programs and a key factor in being ranked #1 in New York State for the past 17 years and #3 in the nation since 2013 by U.S.News & World Report.
    [Show full text]